Lipocine Profit Margin

The latest profit margin for LPCN is -755.13% as of June 2026. That compares with -107.11% in the prior-year period — down 605.0% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Lipocine's historical trend and sector peers before judging valuation or financial health.

Over the past year, LPCN's profit margin moved from -107.11% to -755.13% — a 605.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lipocine's valuation or profitability profile.

Against Healthcare companies, LPCN currently prints -755.13% for profit margin, while the sector average sits near 13.89%. That is roughly 5536.4% below the sector mean. Large gaps often invite a closer look at Lipocine's growth, margins, and balance sheet.

Profit Margin shows how effectively Lipocine converts resources into returns. At -755.13%, LPCN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -107.11% in the prior-year period — down 605.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting LPCN's profit margin (-755.13%), review year-over-year change from -107.11%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.